Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector4247310.18821/1028-9984-2019-24-3-6-74-78Clinical investigationsКлинические исследованияResearch ArticleComparative analysis of the receptor status of the primary focus and synchronous axillary metastases in breast cancer patientsСравнительный анализ рецепторного статуса первичного очага и синхронных подмышечных метастазов у больных раком молочной железыhttps://orcid.org/0000-0003-4453-6205Krumin’Yu. S.КруминьЮ. С.
Russian Federation

MD, postgraduate student

аспирант

krumin.iulia@yandex.ruKhailenkoV. A.ХайленкоВ. А.
Russian Federation
krumin.iulia@yandex.ruKozlovN. A.КозловН. А.
Russian Federation
krumin.iulia@yandex.ruCheremisG. Yu.ЧеремисГ. Ю.
Russian Federation
krumin.iulia@yandex.ruKhailenkoD. V.ХайленкоД. В.
Russian Federation
krumin.iulia@yandex.ruArtamonovaE. V.АртамоноваЕ. В.
Russian Federation
krumin.iulia@yandex.ruKovalenkoE. I.КоваленкоЕ. И.
Russian Federation
krumin.iulia@yandex.ruKovalenkoI. P.КоваленкоИ. П.
Russian Federation
krumin.iulia@yandex.ruBokhyanV. Yu.БохянВ. Ю.
Russian Federation
krumin.iulia@yandex.ruPirogov Russian National Research Medical UniversityФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииN.N. Blokhin National Medical Research Center of OncologyФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Министерства здравоохранения Российской Федерации18072019243-6747818082020Copyright ©; 2019, Eco-VectorCopyright ©; 2019, ООО "Эко-Вектор"2019Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/42473

The aim of the investigation. To study concordance of surrogate molecular subtype in the pairs of primary and synchronous axillary metastases in patients with invasive breast cancer (IBC).

Materials and methods. Retrospective analysis included 80 patients aged 28 to 90 years (average age 40.3±5.3 years) with a first-time diagnosed IBC who underwent surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology during 2016–2018 years. None of the patients received any neoadjuvant drug therapy. The pathological evaluation of the estrogen receptors (ER), progesterone receptor (PR), HER2 expression and estimation of proliferative activity (Ki-67 index) with subsequent assignment to surrogate subtypes were performed according to ASCO/CAP protocols and the recommendations of the 2013–2019 San-Gallen Conference on treatment of Early Breast Cancer.

Results. Preliminary results of our study revealed therapeutically significant changes in hormone receptor status, HER2-status and proliferative activity in 12.5% of cases of Luminal A type IBC, 20% of Luminal B/HER2-positive and 4% of Luminal B/Her2-negative subtypes of IBC.

Цель исследования. Изучить конкордантность суррогатного молекулярного подтипа первичного очага и синхронных подмышечных метастазов у больных раком молочной железы (РМЖ).

Материалы и методы. Проведён ретроспективный анализ группы из 80 пациенток в возрасте от 28 до 90 лет (средний возраст 40,3±5,3 лет) с впервые выявленным диагнозом РМЖ, до получения неоадъювантной терапии, проходивших лечение в 2016–2018 гг. в НМИЦ онкологии им. Н.Н. Блохина. Оценка экспрессии рецепторов эстрогенов (ER), прогестерона (PR), онкобелка Her2/neu, индекса пролиферации (индекс Ki-67) и распределение на суррогатные подтипы были выполнены в соответствии со стандартными протоколами ASCO/CAP и рекомендациями Сан-Галленовской конференции 2013–2019 гг.

Результаты. Результаты проведённого нами исследования позволили выявить терапевтически значимые изменения в рецепторном статусе и пролиферативной активности в 12,5% случаев люминального А типа, 20% люминального В/Her2-позитивного и 4% люминального В/Her2-негативного типов РМЖ.

breast cancerERPRKi67Her2 receptor statusimmunohistochemical subtypes of breast cancerрак молочной железырецепторный статус опухоли ERPRKi-67Her2суррогатные подтипы рака молочной железыKaprin A.D., Starinskij V.V., Petrova G.V., red. Cancer in Russia in 2018 (morbidity and mortality). [ Zlokachestvennye novoobrazovanija, zabolevaemost’ i smertnost’] M.: MNIOI im. P.A. Gercena filial FGBU «NMIC radiologii» 2018. Available at: https://www.oncology.ru/service/statistics/malignant_tumors/2018.pdf (In Russian)Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2018 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018.Available at: https://www.oncology.ru/service/statistics/malignant_tumors/2018.pdfO’Neill F., Madden S.F., Clynes M. et all. A gene expression profile indicative of early stage HER2 targeted therapy response. Mol. Cancer. 2013; 12: 69.O’Neill F., Madden S.F., Clynes M. et al. A gene expression profile indicative of early stage HER2 targeted therapy response. Mol. Cancer. 2013; 12: 69.Strehl J.D., Wachter D.L., Fasching P.A. et all. Invasive Breast Cancer: Recognition of Molecular Subtypes. Breast Care (Basel). 2011; 6 (4): 258–64.Strehl J.D., Wachter D.L., Fasching P.A. et al. Invasive Breast Cancer: Recognition of Molecular Subtypes. Breast Care (Basel). 2011; 6 (4): 258–64.Perou C. M., Sørlie T., M. B. Eisen et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747–52.Perou C.M., Sørlie T., M.B. Eisen et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747–52.Burrell R. A., Mcgranahan N., Bartek J. et al. The causes and consequences of genetic. Nature. 2013; 501: 338–45.Burrell R.A., Mcgranahan N., Bartek J. et al. The causes and consequences of genetic. Nature. 2013; 501: 338–45.Marusyk A., Polyak K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta – Rev. Cancer. 2010; 1805 (1): 105–17.Marusyk A., Polyak K. Tumor heterogeneity: Causes and consequences.Biochim. Biophys. Acta – Rev. Cancer. 2010; 1805 (1): 105–17.Meacham C.E., Morrison S. J. Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501 (7467): 328–37.Khrakhmal’ N.V., Zavyalova M.V., Denisov E.V. et al. Invasion of tumor epithelial cells: mechanisms and manifestations. Acta Naturae. 2015; 2 (25): 18–31. (In Russian)Крахмаль Н.В., Завьялова М.В., Денисов Е.В. и др. Инвазия опухолевых эпителиальных клеток: механизмы и проявления. Acta Naturae 2015; 2 (25): 18–31.Kuligina E. sh. Epidemiological and molecular aspects of breast cancer. Practical Oncology. 2010; 11(4): 203–16 (In Russian)Кулигина Е.Ш. Эпидемиологические и молекулярные аспекты рака молочной железы. Практическая онкология. 2010; 11 (4): 203–16.Khan A., Ellis I.O., Hanby A.M., Cosar E.F., Rakha E.A., Kandil D. Precision Molecular Pathology of Breast Cancer. 2015; 81: 107–12.Moskvina L.V., Andreeva Yu.Yu., Zavalishina L.E., Ilatovskaya M., Frank G. Breast cancer intratumoral heterogeneity in routine practice. Virchows Archiv. 2016; 469 (Suppl.1): S56.Strehl J.D., Wachter D.L., Fasching P.A. et al. Invasive Breast Cancer: Recognition of Molecular Subtypes. Breast Care (Basel). 2011; 6 (4): 258–64.Islam T., Matsuo K., Ito H., Hosono S., Watanabe M., Iwata H., Tajima K., Tanaka H. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negativebreast cancer in Japanese women. Ann. Oncol. 2012; 23 (9): 2435–41.Coates A.S., Colleoni M., Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal a breast cancer. J. Clin. Oncol. 2012; 30: 1–4.Coates A.S, Colleoni M., Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal a breast cancer. J. Clin. Oncol. 2012; 30: 1–4.Lower E.E., Glass E.L., Bradley D.A., Blau R., Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Research and Treatment. 2005; 90 (1): 65–70.Guarneri V., Piacentini F., Ficarra G. et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann. Oncol. 2008; 20: 1193–8.Lower E.E., Glass E., Blau R., Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Research and Treatment. 2009; 113 (2): 301–6.Neubauer H., Gall C., Vogel U., Hornung R., Wallwiener D., Solomayer E., Fehm T. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008; 28 (3B): 1797–804.Neubauer H., Gall C., Vogel U., Hornung R., Wallwiener D., Solomayer E., Fehm T. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008; 28(3B): 1797–804.Burcombe R.J., Makris A., Richman P.I. et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer. 92 (2005), 147–55.Burcombe R.J., Makris A., Richman P.I. et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer. 2005; 92: 147–55.Ellis M.J., Coop A., Singh B., Tao Y., Llombart-Cussac A., Jänicke F. et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003; 63: 6523–31.Dardes R.D., Horiguchi J., Jordan V.C. A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer. Int. J. Oncol. 2000; 16: 25–30.Hammond M.E., Hayes D.F., Wolff A.C., Mangu P.B., Temin S. ASCO/CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 2010; 6 (4): 195–7.Balic M., Thomssen C., Würstlein R., Gnant M., Harbeck N. St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. Breast Care (Basel). 2019; 14 (2): 103–10.Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H. et al. ASCO/CAP Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31: 3997–4013.Amir E., Miller N., Geddie W. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 2012; 30: 587–92. doi:10.1200 JCO.2010.33.5232Allred D.C. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod. Pathol. 2010; 23 (Suppl 2): S52–S59.Muller K.E., Marotti J.D., Memoli V.A. et al. Impact of the 2013 ASCO/CAP HER2 guideline updates at an academic medical center that performs primary HER2 FISH testing: increase in equivocal results and utility of reflex immunohistochemistry. Am. J. Clin. Pathol. 2015; 144 (2): 247–52Long T.H., Lawce H., Durum C. et al. The new equivocal: changes to HER2 FISH results when applying the 2013 ASCO/CAP Guidelines. Am. J. Clin. Pathol. 2015; 144 (2): 253–62